Autoimmune-Summaries: Daily Autoimmune Updates at a Glance
- decodeMR Team
- 8 hours ago
- 1 min read
20/05/2026
Savara presented biomarker data from the Phase 3 trial of molgramostim inhalation solution in aPAP at the ATS International Conference 2026 (Ref)
Savara presented a poster at American Thoracic Society (ATS) International Conference 2026. The poster reported new biomarker data from the Phase 3, IMPALA-2, double blind study which evaluated molgramostim inhalation solution (Molgramostim) for the treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP).
Biomarker levels associated with aPAP disease severity decreased and improvements in pulmonary gas transfer were observed in patients treated with molgramostim.
